Clik here to view.
AVITA Medical Announces Expansion of Management Team to Support Planned U.S....
VALENCIA, Calif. & MELBOURNE, Australia AVITA Medical (ASX: AVH) (OTCQX: AVMXY) today announced that it expanded its management team in the commercial, legal and medical affairs functions to...
View ArticleClik here to view.
Alpine Immune Sciences Completes Sale of S-Nitrosoglutathione Reductase...
SEATTLE & HANGZHOU, China Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a company focused on discovering and developing innovative, protein-based immunotherapies to treat cancer,...
View ArticleClik here to view.
Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint...
CAMBRIDGE, Mass. & OSAKA, Japan Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the global, randomized, Phase 3 ALTA-1L (ALK in Lung Cancer Trial of AP26113 in 1st Line)...
View ArticleClik here to view.
NeuroVia Initiates Phase 1/2 Trial of NV1205 for Treating Childhood Cerebral...
SAN FRANCISCO NeuroVia, Inc., a biopharmaceutical company focused on developing innovative therapies for rare, genetic neurological diseases, today announced the initiation of a Phase 1/2 clinical...
View ArticleClik here to view.
Dr. Reddy’s Laboratories Announces the Launch of Hervycta® (trastuzumab...
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY) announced today that it has launched Hervycta® (trastuzumab), a biosimilar of Roche’s Herceptin®, in India, indicated for...
View ArticleClik here to view.
Pierre Fabre receives positive CHMP opinion for BRAFTOVI® (encorafenib) +...
CASTRES, France Pierre Fabre today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval of...
View ArticleClik here to view.
武田薬品、ALUNBRIG®（ブリガチニブ）の第3相試験が主要評価項目を達成し、ALK阻害剤未治療の進行性ALK陽性NSCLC患者でクリゾチニブと比較して...
米マサチューセッツ州ケンブリッジ & 大阪 （ビジネスワイヤ） — 武田薬品工業株式会社（TSE: 4502）は本日、グローバルランダム化第3相ALTA-1L試験（ALK in Lung Cancer Trial of AP26113 in 1st...
View ArticleClik here to view.
武田宣布3期ALUNBRIG®...
马萨诸塞州剑桥和日本大阪 (美国商业资讯) — 武田药品工业株式会社(TSE: 4502)今天宣布，全球随机3期ALTA-1L（ALK in Lung Cancer Trial of AP26113 in 1st...
View ArticleClik here to view.
Astex Pharmaceuticals and Otsuka Announce Results of the Phase 3 ASTRAL-1...
PLEASANTON, Calif. & TOKYO Astex Pharmaceuticals, a member of the Otsuka group of companies, and Otsuka Pharmaceutical Co. Ltd., announce top-line results from the ASTRAL-1 study evaluating the...
View ArticleClik here to view.
Takeda Reports First Quarter FY2018 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth +6.4% with growth in every region Underlying Revenue grew +6.4%, led by Takeda’s Growth Drivers...
View ArticleClik here to view.
2018年度第1四半期（4-6月期）の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 実質的な売上収益は＋6.4％、すべての地域で増収 売上収益の実質的な成長は、タケダの成長ドライバー（消化器系疾患領域、オンコロジー、ニューロサイエンス、新興国事業）の＋11.8％の力強い伸長により、対前年同期＋6.4％、主力製品であるエンティビオ（＋34.1％）およびニンラーロ（＋43.3％）が大きく貢献...
View ArticleClik here to view.
Infraredx Announces Launch of Makoto™ Intravascular Imaging System and...
BURLINGTON, Mass. Infraredx, Inc., a pioneer in intravascular imaging for mapping coronary artery disease, today announced the Makoto™ Intravascular Imaging System, and accompanying Dualpro™...
View ArticleClik here to view.
CANbridge Life Sciences Appoints Chief Medical Officer
BEIJING CANbridge Life Sciences, a biopharmaceutical company developing Western drug candidates in China and North Asia, announced that it strengthened the executive management team with the...
View ArticleClik here to view.
武田公布2018财年第一季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited, TOKYO:4502)： 基础营收增长+6.4%，各个地区均有增长 基础营收增长+6.4%，武田的增长引擎（胃肠药、肿瘤药、神经科药物和新兴市场）与前一年相比展现了强劲增长，增幅达到+11.8%。主要产品Entyvio (+34.1%)和Ninlaro...
View ArticleClik here to view.
Clover Biopharmaceuticals Initiates Phase I Study of Etanercept Biosimilar...
CHENGDU, China Clover Biopharmaceuticals, a biotechnology company focused on developing novel and transformative biologic therapies, today announced that the first patient was dosed in a Phase I...
View ArticleClik here to view.
Shionogi Announces FDA Approval of Mulpleta® (Lusutrombopag)
OSAKA, Japan & FLORHAM PARK, N.J. Shionogi & Co., Ltd. (hereafter “Shionogi”) announced today that, after completing a Priority Review, the U.S. Food and Drug Administration (FDA) has...
View ArticleClik here to view.
Genome Editing Biotech EdiGene Names Dong Wei, Ph.D., MBA as its Chief...
BEIJING & CAMBRIDGE, Mass. EdiGene Inc., which develops genome editing technologies into novel therapeutics for a broad range of diseases and into creative solutions to advance drug discovery,...
View ArticleClik here to view.
Glaukos Announces Pharmaceutical Development Agreement with D. Western...
SAN CLEMENTE, Calif. Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on the development and commercialization of novel surgical devices and...
View ArticleClik here to view.
KIST: Overcoming the Current Limitations of Cancer Immunotherapy Through...
SEOUL, South Korea Cancer immunotherapy harnessing the immune system to treat cancer is drawing a lot of attention of many medical staff and researchers because of unprecedented responses in the...
View ArticleClik here to view.
ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Exclusive License...
SAN DIEGO & MELBOURNE, Australia ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) and Neuren Pharmaceuticals Limited (ASX: NEU) announced today that they have entered into an exclusive North American...
View Article